Letter

The neutrophil-to-lymphocyte ratio at the prostate-specific antigen nadir predicts the time to castration-resistant prostate cancer

Dear editor,

With the spread of prostate-specific antigen (PSA) screening, an increasing number of early-stage prostate cancers have been diagnosed recently, although many patients are still diagnosed in the advanced stage [1]. Although most prostate cancers with metastatic lesions respond to initial androgen ablation therapy, responders ultimately develop progressive disease due to hormone-refractory cancer. Recent studies have shown the efficacy of initial docetaxel or abiraterone acetate with predonine in metastatic hormone-sensitive prostate cancer (mHSPC) [2]. However, not all mHSPC patients experience efficacy with this up-front initial treatment. These previous studies have therefore underscored the importance of assessing the risk of castration-resistant prostate cancer (CRPC) in mHSPC patients.

A recent study reported that the neutrophil-to-lymphocyte ratio (NLR) was an independent prognostic factor in some solid malignancies, including prostate cancer [1]. A recent study revealed the usefulness of the NLR for prostate cancer patients who were candidates for active surveillance [3]. Our previous study also showed that the group with a higher NLR showed a poorer recurrence-free and overall survival in mHSPC. Although these reports showed the importance of properly assessing prognostic factors, they did not investigate the NLR values in the course of cancer therapy. The present study was the first to examine the NLR over the course of treatment in the same mHSPC patient cohort: When they were first diagnosed, when the PSA level was at its nadir, and when they developed CRPC status.

We retrospectively reviewed 46 consecutive patients with initially diagnosed metastatic prostate cancer from 2004 to 2016, at Yokohama City University Medical Center (Yokohama, Japan) and Yokohama City University Graduate School of Medicine (Yokohama, Japan). All patients were administered androgen deprivation therapy (ADT). None of the patients received up-front docetaxel or up-front abiraterone therapy. The PSA nadir was determined as the time when the patients’ PSA level was lowest after ADT. The CRPC day was determined as the time when the PSA level was its nadir value +2 ng/mL or when the drug regimen was changed. This study was carried out in accordance with the ethical standards of the Declaration of Helsinki. The review board of Yokohama City University (D15060003) approved this study.

A total of 138 patients with initially diagnosed metastatic prostate cancer were enrolled in this study. Of these patients, 46 had available data for their NLR over the course of prostate cancer treatment (Supplementary Table 1). The median values were used as the cut-off points for the NLR. The higher NLR group (≥1.73 at the time of PSA nadir) showed a significantly longer time from the initial diagnosis to CRPC as well as from the PSA nadir to CRPC than the lower NLR group (<1.73 at the time of PSA nadir) (p=0.042 and p=0.046, respectively) (Fig. 1A and 1B). The NLR at the time of PSA nadir was significantly lower than that at the diagnosis (p<0.001), and the PSA values were remeasured at the time of CRPC (p=0.008) (Fig. 1C). In addition, a high NLR at the time of the PSA nadir was an independent risk factor for a short time to CRPC (Supplementary Table 2). We therefore speculated that the NLR was correlated with prostate cancer aggressiveness.

While the detailed mechanisms remain unclear, one candidate mechanism underlying this relationship is that a lower lymphocyte count reduces the immunoreactivity and thereby results in cancer progression [4]. Though tumor invasive dendric cells induced acquired immunity and suppressed tumor progression, transforming growth factor (TGF)-beta and prostaglandin E2 (PGE2) changed the dendric cells and induced regulatory T cells (regT) [5]. RegT...
increased again by the point of CRPC (significantly lower than the NLR at the diagnosis (respectively. The NLR at the time of the PSA nadir was significantly lower than the NLR at the diagnosis (p < 0.001) but increased again by the point of CRPC (p = 0.008).

Figure 1 The results of neutrophil-to-lymphocyte ratio (NLR) and prostate-specific antigen (PSA) in castration-resistant prostate cancer (CRPC) and NLR group. (A) The lower NLR value group (<1.73) showed a longer time from the initial diagnosis to CRPC than the higher NLR group (≥1.73) (median time: 1067 vs. 426 days, p = 0.042); (B) The lower NLR value group (<1.73) showed a longer time from the PSA nadir to CRPC than the higher NLR group (≥1.73) (median time: 426 vs. 215 days, p = 0.046); (C) The NLRs at the time of the diagnosis, PSA nadir, and CRPC were 3.36±1.77, 2.24±1.27, and 3.06±1.85, respectively. The NLR at the time of the PSA nadir was significantly lower than the NLR at the diagnosis (p < 0.001) but increased again by the point of CRPC (p = 0.008).

The NLR is thought to be an important prognosis predictive marker for advanced disease or CRPC. Previous reports [7–9] discussed that NLR is easily calculated and no additional costs are required and widely used in urological field. Furthermore, an increased NLR has been shown to be associated with a worse overall, cancer specific survival, and recurrence-free survival [10]. However, despite these previous findings concerning the importance of the NLR, no previous study has described the changes in the NLR induced by cancer therapy. The present study showed that the NLR was correlated with prostate cancer progression in metastatic prostate cancer patients who developed CRPC.

Author contributions

Study design: Genta Iwamoto, Takashi Kawahara.

Data acquisition: Genta Iwamoto, Takashi Kawahara, Yumiko Yokomizo, Yasuhide Miyoshi, Hiroji Uemura.

Data analysis: Genta Iwamoto, Takashi Kawahara.

Drafting of manuscript: Genta Iwamoto, Takashi Kawahara.

Critical revision of the manuscript: Masahiro Yao.

Conflicts of interest

The authors declare no conflict of interest.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.ajur.2020.05.006.

References

[1] Kawahara T, Yokomizo Y, Ito Y, Ito H, Ishiguro H, Teranishi J, et al. Pretreatment neutrophil-to-lymphocyte ratio predicts the prognosis in patients with metastatic prostate cancer. BMC Canc 2016;16:111. https://doi.org/10.1186/s12885-016-2134-3.

[2] Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 2017;377: 352–60.

[3] Gokce M, Tangal S, Hamidi N, Suer E, Ibis MA, Beduk Y. Role of neutrophil-to-lymphocyte ratio in prediction of Gleason score upgrading and disease upstaging in low-risk prostate cancer patients eligible for active surveillance. Can Urol Assoc J 2016; 10:E38–7. https://doi.org/10.5489/cuaj.3550.

[4] Pond GR, Berry WR, Galsky MD, Wood BA, Leopold L, Sonpavde G. Neutropenia as a potential pharmacodynamic marker for docetaxel-based chemotherapy in men with metastatic castration-resistant prostate cancer. Clin Genitourin Canc 2012;10:239–45.

[5] Scarlett UK, Rutkowski MR, Rauwerdink AM, Fields J, Escobar-Fadul X, Baid J, et al. Ovarian cancer progression is controlled by phenotypic changes in dendritic cells. J Exp Med 2012;209:495–506.

[6] Nishikawa H, Jager E, Ritter G, Old LJ, Gnajtic S. CD4+ CD25+ regulatory T cells control the induction of antigen-specific CD4+ helper T cell responses in cancer patients. Blood 2005;106:1008–11.

[7] Cantiello F, Russo GI, Vartolomei MD, Farhan ARA, Terracciano D, Musi G, et al. Systemic inflammatory markers and oncologic outcomes in patients with high-risk non-muscle-invasive urothelial bladder cancer. Eur Urol Oncol 2018;1:403–10.

[8] Ferro M, Musi G, Serino A, Cozzi G, Mistretta FA, Costa B, et al. Neutrophil, platelets, and eosinophil to lymphocyte ratios predict gleason score upgrading in low-risk prostate cancer patients. Urol Int 2019;102:43–50.

[9] Vartolomei MD, Ferro M, Cantiello F, Lucarelli G, Di Stasi S, Hurle R, et al. Validation of neutrophil-to-lymphocyte ratio in a multi-institutional cohort of patients with T1G3 non-muscle-invasive bladder cancer. Clin Genitourin Canc 2018;16:445–52.

[10] Gu X, Gao X, Li X, Qi X, Ma M, Qin S, et al. Prognostic significance of neutrophil-to-lymphocyte ratio in prostate cancer: evidence from 16,266 patients. Sci Rep 2016;6:22089. https://doi.org/10.1038/srep22089.

Genta Iwamoto

Department of Urology and Renal Transportation,
Yokohama City University Medical Center, Yokohama,
Kanagawa, Japan

Takashi Kawahara*

Department of Urology and Renal Transportation,
Yokohama City University Medical Center, Yokohama,
Kanagawa, Japan

Graduate School of Medicine, Yokohama, Kanagawa, Japan
Yumiko Yokomizo  
Department of Urology, Yokohama City University  
Graduate School of Medicine, Yokohama, Kanagawa, Japan

Yasuhide Miyoshi  
Department of Urology and Renal Transportation,  
Yokohama City University Medical Center, Yokohama, Kanagawa, Japan

Masahiro Yao  
Department of Urology, Yokohama City University  
Graduate School of Medicine, Yokohama, Kanagawa, Japan

Hiroji Uemura  
Department of Urology and Renal Transportation,  
Yokohama City University Medical Center, Yokohama, Kanagawa, Japan

*Corresponding author. Departments of Urology and Renal Transplantation, Yokohama City University Medical Center, Yokohama, Kanagawa, Japan.  
E-mail address: takashi_tk2001@yahoo.co.jp (T. Kawahara)  
28 May 2019